The 2008 Journal of the National Cancer Institute guidelines recommend time to progression (TTP) in the randomized phase II setting for intermediate hepatocellular carcinoma (HCC).1 PREMIERE complied with the recommendation and was initiated in 2009. It is the first real-life comparative effectiveness randomized study comparing Y90 with the standard of care conventional transarterial chemoembolization (cTACE).2 We acknowledge the limitations of our trial and are happy reply to the comments.